V
35.56
3.68 (11.54%)
| Previous Close | 31.88 |
| Open | 34.31 |
| Volume | 8,406,967 |
| Avg. Volume (3M) | 3,594,545 |
| Market Cap | 3,998,544,384 |
| Price / Book | 3.35 |
| 52 Weeks Range | |
| Earnings Date | 22 Oct 2025 |
| Diluted EPS (TTM) | -1.54 |
| Total Debt/Equity (MRQ) | 0.11% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -152.54 M |
| Levered Free Cash Flow (TTM) | -102.10 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -19.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Viking Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
0.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 70.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 122.00 (Raymond James, 243.08%) | Buy |
| Median | 102.00 (186.84%) | |
| Low | 38.00 (Citigroup, 6.86%) | Hold |
| Average | 87.33 (145.59%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 30.45 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Aug 2025 | 102.00 (186.84%) | Buy | 24.36 |
| 25 Jun 2025 | 102.00 (186.84%) | Buy | 27.09 | |
| Citigroup | 24 Jul 2025 | 38.00 (6.86%) | Hold | 33.50 |
| Raymond James | 24 Jul 2025 | 122.00 (243.08%) | Buy | 33.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Viking Therapeutics to Participate at Upcoming Investor Conferences |
| 24 Aug 2025 | CNBC | Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors |
| 19 Aug 2025 | Announcement | Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity |
| 19 Aug 2025 | CNBC | Viking Therapeutics shares fall 40% on disappointing obesity pill trial data |
| 07 Aug 2025 | CNBC | Eli Lilly shares drop after obesity pill shows modest late-stage trial results |
| 23 Jul 2025 | Announcement | Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 16 Jul 2025 | Announcement | Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 |
| 25 Jun 2025 | Announcement | Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |